In this study, the feasibility of constructing radioimmunoconjugates by using the novel therapeutic candidate alpha-emitter, 227 
INTRODUCTION
Dosimetric modeling and preclinical studies have indicated that alpha-emitting radionuclides could be a promising alternative to beta-emitters in the treatment of minimal disease by radioimmunotherapy. [1] [2] [3] [4] The range of alpha-emitters are typically less than 100 m in tissue. This range is well matched with the size of micrometastases, indicating the potential for a more tumor-selective irradiation. Therefore, there is an increasing interest toward applying alpha-emitters in cancer therapy. Some challenges have halted the progress in the biomedical application of alpha-emitters. 5 Notable are the low availability of radionuclides with proper physical and chemical characteristics, supply limitations, and expenses for the most popular alpha-emitters, 211 At (t 1 / 2 , 7.2 hours), 213 Bi (t 1 / 2 , 46 minutes), and 225 Ac (t 1 / 2 , 10 days). Also, because of the short half-lives and/or limited chemical yields, the production of a final product in clinically useful quantities has been problematic. Therefore, attention has been brought to alpha-emitters that can be prepared in large quantities from long-term operating generators, such as 223 Ra (t 1 / 2 , 11.4 days), 224 Ra (t 1 / 2 , 3.7 days), and 212 Bi (t 1 / 2 , 60.6 minutes), as well as the alpha-emitter generator, 212 Pb (t 1 / 2 , 10.6 hours). 6, 7 Owing to the lack of stable complexing agents, radium isotopes have, thus far, not been applied in radioimmunotherapy. 4 In a previous study, we showed that the precursor of 223 Ra, 227 Th, could be used as a bone-seeker when complexed with a bone-seeking chelate. 8 Thorium-227 has a halflife of 18.7 days and can be produced in practically unlimited amounts from 227 Ac, which is generated by the thermal neutron irradiation of 226 Ra. The physical characteristics of 227 Th and its daughter nuclides is presented in Table 1 .
Thorium is an actinide, but its chemical properties are, to some extent, different from that of actinium. Thorium predominately exists as 4 ϩ , whereas Ac is present as 3 ϩ in aqueous solution. Therefore, there could be differences in the reactivity and stability with various complexing agents. McDevitt et al. demonstrated that 225 Ac could be conjugated to monoclonal antibodies (mAbs) with a DOTA chelator by changing reaction conditions. 9 The complex needed significant heating to obtain a more stable configuration, which implied that the reaction had to be performed in a two-step sequence by combining the radionuclide and the chelator first at an elevated temperature that would have been destructive to proteins. Subsequently, after cooling down the reaction mixture, the conjugation of the radiolabeled complex to the antibody could be performed. The aim of this study was to use a twostep reaction sequence to conjugate 227 Th to antibodies. This study presents data regarding chemical yield, cell-binding properties, and in vitro stability by the testing of two mAbs labeled with 227 Th with the chelator, p-SCN-benzyl-DOTA.
MATERIALS AND METHODS

Preparation of 227 Th
227 Ac was produced through the thermal neutron irradiation of 226 Ra, followed by the ␤ Ϫ decay of 227 Ra (t 1 / 2 , 42.2 m) to 227 Ac. 8 227 Th was selectively retained from a 227 Ac decay mixture in 7 M of HNO 3 solution by anion exchange chromatography. A column of 2 mm of internal diameter, a length of 30 mm and containing 70 mg of AG-1 ϫ 8 resin (200-400 mesh; nitrate form) was used (Dowex AG-1X8; Dow Horgen, Switzerland). After 227 Ac, 223 Ra, and their daughters had eluted from the column, 227 Th was extracted from the column with 12 M of HCl. The eluate containing 227 Th was evaporated to dryness, and the residue was resuspended in 0.01 M of HCl. In general, the 227 Th was purified with an almost quantitative yield by this method.
Preparation of 227 Th-DOTA Complex
High-purity water (Fluka AG; Buchs, Switzerland) was used to prepare the reagent solution applied in the preparation of the 227 Th-DOTA complex. The 227 Th-DOTA complex was prepared by adding 20 L of a 10 mg/mL solution of 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-benzyl-DOTA; Macrocyclics Inc., Dallas, TX) to a solution containing 20 L (150 mg/mL) of Lascorbic acid (Sigma-Aldrich Co. Ltd.; Gillingham, United Kingdom) and 20-150 L of 100-300 MBq/mL 227 Th in 0.05 M of HCl in a 2 mL glass vial. The pH was adjusted to approximately 5.5 by adding tetramethylammonium acetate (Aldrich Chemical Co.; Milwaukee, WI). Thereafter, the reaction mixture was incubated for 40 minutes at approximately 55°C by using a Thermomixer Comfort (Eppendorf AG; Hamburg, Germany).
Conjugation of 227 Th to Antibodies
The two commercially available antibodies, rituximab (Mabthera ® ; Roche, Basel, Switzerland) and traztuzumab (Herceptin ® ; Roche, Switzerland) were used in this study. Rituximab could be used as provided from the manufacturer, whereas trastuzumab was subject to buffer exchange by using 0.05 M of phosphate-buffered saline (PBS), because the original buffer contained significant amounts of free amino acid that might have interfered with the chelator conjugation. In brief, 1 mL of trastuzumab (21 mg/mL) was added to 4 mL of PBS and transferred to an Amicon Ultra-15 concentrating tube (MWCO 30,000; Millipore, Carrigthwohill, Co., Cork, Ireland). After centrifugation (Eppendorf Centrifuge 5810 R; Eppendorf AG, Hamburg, Germany) until a volume of 1 mL was achieved, the procedure was repeated twice.
The reaction solution containing 227 Th and p-SCN-benzyl-DOTA was cooled down to 37°C, 0.5-2 mg of antibody in 100-200 L was added, and the pH was adjusted to 8-9 by adding 1 M of NaCO 3 /NaHCO 3 buffer. The specific activity of the radioimmunoconjugate was typically 500-1000 Bq/g. After 45 minutes of reaction, 20 L of saturated diethylene-triaminepentaacetic acid (DTPA; Fluka Chemie, Buchs, Switzerland) was added and the mixture was further incubated for 5 minutes. Thereafter, the reaction mixture was purified by gel filtration (Econo-Pac10 DG; Bio-Rad, Hercules, CA) eluted with 1% bovine serum albumin (BSA; Sigma Chemical Co., St Louis, MO) in PBS at a pH of 7.4. Finally, the purified product was sterile filtered (Millex GV-13; Millipore Co, Bedford, IL) into a sterile 10 mL glass vial (Wheaton; Millville, NJ), which was subsequently capped with a sterile rubber cap.
High-Performance Liquid Chromatography (HPLC)
High-performance liquid chromatography (HPLC) analyses were performed using a Rheodyne injector (Rohnert Park; CA), an LC10 pump, a SPD10A UV/Vis detector, a SPD10Avp controller, and a class VP version 5.032 software, all purchased from the Shimadzu Corporation (Kyoto, Japan). A TSK-GEL G3000SW ϫ l size exclusion column (Supelco Inc.; Bellefonte, PA) as the stationary phase and PBS pH 7.4/0.1 M Na 2 SO 4 /0.5% NaN 3 as the mobile phase were used at a pump velocity of 1 mL/minutes. For radioactivity measurements, 0.5-mL fractions were collected and measured on the gamma-counter.
In Vitro Stability Testing
To each sterile 2 mL vial (Nalgene Cryoware; Nalge Company, Rochester, NY) 1 mL of fetal bovine serum (FBS) and approximately 20 kBq of radioimmunoconjugate was added. The vials were kept at 37°C for the entire incubation period. At each measured time point, the vials were counted using a solid-state photon detector GEM-50 (Ortec; Oak Ridge, TN) with a digital gammaray spectrometer (Dispec, Jr.; ORTEC, Oak Ridge, TN) and Gammavision-32 Version 6.01 software (Ortec). Subsequently, 20 L of DTPA was added and further incubated for 5-10 minutes and purified though a 10 DG column (BioRad Laboratories, Hercules, CA) in one experiment, and in the second experiment, a Sephadex G-25 PD-10 (Amersham Biosciences, Uppsala, Sweden), by elution with 1% BSA (SigmaAldrich) in physiologic saline. The protein fraction was collected and the fractions counted on the Ge-detector. The percentage of 227 Th activity in the antibody fractions versus the total 227 Th prior to purification was determined by comparing the net count rates in the 236-keV gamma peak.
Cell Lines
Raji CD-20 antigen-positive lymphoma cells and BT-474 HER-2-positive breast cancer cells were used to evaluate the antigen-binding fractions. MCF-7 cells with a lower expression of HER-2 were also used. The cells were grown in 75 cm 2 flasks containing 10 mL of RPMI 1640 medium (Gibco; Invitrogen, Carlsbad, CA), supplied with 13% FBS (Gibco) and Glutamax (Gibco). Raji cells were grown in suspension, whereas BT-474 and MCF-7 cells were adherent. The cell lines were obtained from American Type Culture Collection (ATCC; LGC PromoChem AB, Boras, Sweden).
Determination of Antigen-Binding Fraction
Determination of the antigen-binding fraction was performed in a one-concentration point assay. 10 Reaction tubes (1-3 replicas) were added to a 0.25-0.4 mL cell suspension with 40-100 million cells/mL of RPMI medium and 20-500 ng of freshly made radiolabeled antibody and incubated for approximately 2 hours at 4°C. If the radioimmunoconjugate was older than 24 hours, it was purified prior to use. To determine nonspecific binding, cell suspensions were preincubated for 15 minutes with 25 g of unlabeled antibody to block the antigens. In some experiments, nonspecific binding was assessed by incubating cell suspensions with 20-500 ng of radiolabeled unspecific antibody; Raji cells with trastuzumab, and BT-474 and MCF-7 cells with rituximab, respectively. The samples were measured using a gamma-counter (Crystal II Multidetector RIA System; Packard Instruments Co., Downers Grove, IL).
RESULTS
Antibody Preparation
The overall labeling yield in the two-step sequence was in the range of 6%-17%. In general, the yield seemed to be better when at least 1 mg of antibody was used in the reaction. There was no significant difference in labeling yield between the two antibodies.
HPLC Analyses
The HPLC profiles showed that the radioimmunoconjugates had the peak at approximately 9.5 minutes, whereas unconjugated p-SCN-benzyl-DOTA appeared at approximately 13 minutes and the free radionuclides after 13.5 minutes. Analyses of freshly purified radioimmunoconjugate indicated one single peak at approximately 9.5 minutes, with no significant activity peaks elsewhere.
In Vitro Stability Testing of Radioimmunoconjugate
In Figure 1 , the assessment of the in vitro stability performed in Ͼ80% FBS is presented. The experiments were done by gel-exclusion separation to determine the fraction of 227 Th that would elute in the protein fraction. Both types of columns used were feasible for separating the radioimmunoconjugate from free 227 Th. To avoid the coelution of loosely associated 227 Th cations with the proteins, DTPA was added as a low-molecular-weight complexing agent, which helped to separate the 227 Th cations from the protein fraction. The data show a stability of 75%-100% of 227 Th in the antibody fraction over several weeks of incubation in serum at 37°C. There were no signs of a decline in the stability over time, suggesting that the 227 Th-DOTA complex may have a relevant stability for in vivo applications in radioimmunotherapy. The stability seemed to increase over time, but was not statistically significant. Table 2 shows the antigen-binding fractions that were measured for various batches of 227 Th-labeled rituximab against Raji lymphoma cells and of 227 Th-labeled trastuzumab against BT-474 and MCF-7 cells. The data are corrected for nonspecific binding, which was generally less than 5%. The data represent batches with specific activity of 750-1500 kBq/g for 227 Th-labeled rituximab and of 100-5000 kBq/g for 227 Th-trastuzumab. A few batches with a low specific activity of 227 Th-trastuzumab showed a low antigen-binding fraction to BT-474 cells, probably because of saturation of the antigens with unlabeled antibodies. The binding fraction that was found was lower for 227 Th-rituximab than for 227 Th-trastuzumab. The higher specific activity used for 227 Thtrastuzumab might explain this discrepancy. However, the antigen-binding fraction of 227 Thrituximab to Raji cells was similar to that found previously with 211 At-labeled rituximab on CD20 antigen-positive cells by using a one-point assay. 10 When 227 Th-rituximab was evaluated according to the Lindmo method, 11 an immunoreactivity of between 56% and 65% was reported. 12 
Antigen-Binding Fraction
DISCUSSION
One of the major challenges in developing alphaemitter-based pharmaceuticals is the limited production capacity that exists for suitable alpha- 227 Th. In the current paper, we suggest the use of 227 Th in radioimmunotherapy. As indicated by the measured antigen-binding fractions, the chemical procedures that were used seemed to result in a product with an antigenbinding ability appropriate for radioimmunotherapy. It was also shown that the stability of the radioimmunoconjugates did not change significantly in FBS at 37°C over time when followed for several weeks, suggesting that the chelator had relevant properties in terms of stability. This has been confirmed in ongoing in vivo studies with 227 Th-labeled rituximab. 12 A potential limitation regarding the labeling procedure is the relatively modest yields achieved. The yields were similar to that seen with 225 Ac when using p-SCN-benzyl-DOTA. 15 However, when considering the robust and scalable method of producing 227 Th, the limited labeling yield should not be a significant barrier to the development and commercial supply of 227 Th-labeled radioimmunoconjugates. One potential problem when using 227 Th would be the generation of a radioactive daughter from the decay of 227 Th. The decay product, 223 Ra, is itself alpha-emitting and would be released from the radioimmunoconjugate owing to the significant recoil energy when 227 Th undergoes alphaemission. Fortunately, 223 Ra is currently under evaluation as a bone-seeking cation that targets osteoblastic skeletal metastases, and has been extensively evaluated in terms of biodistribution and toxicity in animals as well as in patients. 13, 16 These data indicate that there exists a window where 227 Th may be used without causing harmful toxicity.
CONCLUSIONS
In conclusion, this study indicates that 227 Th could be bound to mAbs by the chelator, p-isothiocyanato-benzyl-DOTA, yielding a radioimmunoconjugate of relevant stability and with appropriate antigen-binding ability. In vivo studies of 227 Th-labeled immunoconjugates are, therefore, warranted.
